Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

410 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mapping cellular interactions from spatially resolved transcriptomics data.
Zhu J, Wang Y, Chang WY, Malewska A, Napolitano F, Gahan JC, Unni N, Zhao M, Yuan R, Wu F, Yue L, Guo L, Zhao Z, Chen DZ, Hannan R, Zhang S, Xiao G, Mu P, Hanker AB, Strand D, Arteaga CL, Desai N, Wang X, Xie Y, Wang T. Zhu J, et al. Among authors: arteaga cl. Nat Methods. 2024 Oct;21(10):1830-1842. doi: 10.1038/s41592-024-02408-1. Epub 2024 Sep 3. Nat Methods. 2024. PMID: 39227721
Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment.
Liu S, Xie SM, Liu W, Gagea M, Hanker AB, Nguyen N, Raghavendra AS, Yang-Kolodji G, Chu F, Neelapu SS, Hanash S, Zimmermann J, Arteaga CL, Tripathy D. Liu S, et al. Among authors: arteaga cl. Res Sq [Preprint]. 2023 Feb 14:rs.3.rs-2388864. doi: 10.21203/rs.3.rs-2388864/v1. Res Sq. 2023. Update in: Breast Cancer Res. 2023 Jun 6;25(1):62. doi: 10.1186/s13058-023-01665-w PMID: 36824840 Free PMC article. Updated. Preprint.
Mapping Cellular Interactions from Spatially Resolved Transcriptomics Data.
Zhu J, Wang Y, Chang WY, Malewska A, Napolitano F, Gahan JC, Unni N, Zhao M, Yuan R, Wu F, Yue L, Guo L, Zhao Z, Chen DZ, Hannan R, Zhang S, Xiao G, Mu P, Hanker AB, Strand D, Arteaga CL, Desai N, Wang X, Xie Y, Wang T. Zhu J, et al. Among authors: arteaga cl. bioRxiv [Preprint]. 2024 Jan 25:2023.09.18.558298. doi: 10.1101/2023.09.18.558298. bioRxiv. 2024. Update in: Nat Methods. 2024 Oct;21(10):1830-1842. doi: 10.1038/s41592-024-02408-1 PMID: 37781617 Free PMC article. Updated. Preprint.
Combined inhibition of CDK4/6 and AKT is highly effective against the luminal androgen receptor (LAR) subtype of triple negative breast cancer.
Chica-Parrado MR, Kim GM, Uemoto Y, Napolitano F, Lin CC, Ye D, Bikorimana E, Fang Y, Lee KM, Mendiratta S, Hanker AB, Arteaga CL. Chica-Parrado MR, et al. Among authors: arteaga cl. Cancer Lett. 2024 Nov 1;604:217219. doi: 10.1016/j.canlet.2024.217219. Epub 2024 Sep 6. Cancer Lett. 2024. PMID: 39244005 Free article.
ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers.
Xu Y, Wang Z, Sjöström M, Deng S, Wang C, Johnson NA, Gonzalez J, Li X, Metang LA, Tirado CR, Mukherji A, Wainwright G, Yu X, Yang Y, Barnes S, Hofstad M, Zhu H, Hanker A, He HH, Chen Y, Wang Z, Raj G, Arteaga C, Feng F, Wang Y, Wang T, Mu P. Xu Y, et al. bioRxiv [Preprint]. 2023 Oct 27:2023.10.24.563645. doi: 10.1101/2023.10.24.563645. bioRxiv. 2023. Update in: Cancer Discov. 2024 Aug 2;14(8):1496-1521. doi: 10.1158/2159-8290.CD-23-0539 PMID: 37961351 Free PMC article. Updated. Preprint.
Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.
Zauderer MG, Jegede O, Jackman DM, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Takebe N, Huang R, Carrillo JA, Brenner AJ, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Zauderer MG, et al. Among authors: arteaga cl. JCO Precis Oncol. 2024 Dec;8:e2400327. doi: 10.1200/PO.24.00327. Epub 2024 Dec 18. JCO Precis Oncol. 2024. PMID: 39693587 Clinical Trial.
Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.
Gien LT, Song Z, Poklepovic A, Collisson EA, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Gien LT, et al. Among authors: arteaga cl. JCO Precis Oncol. 2024 Dec;8:e2400514. doi: 10.1200/PO-24-00514. Epub 2024 Dec 12. JCO Precis Oncol. 2024. PMID: 39666929 Clinical Trial.
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C.
O'Hara MH, Jegede O, Dickson MA, DeMichele AM, Piekarz R, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Onitilo A, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. O'Hara MH, et al. Among authors: arteaga cl. Clin Cancer Res. 2025 Jan 6;31(1):56-64. doi: 10.1158/1078-0432.CCR-24-0036. Clin Cancer Res. 2025. PMID: 39437014 Clinical Trial.
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials.
André F, Solovieff N, Su F, Bardia A, Neven P, Yap YS, Tripathy D, Lu YS, Slamon D, Chia S, Joshi M, Chakravartty A, Lteif A, Taran T, Arteaga CL. André F, et al. Among authors: arteaga cl. Ann Oncol. 2025 Jan;36(1):54-64. doi: 10.1016/j.annonc.2024.09.010. Epub 2024 Sep 21. Ann Oncol. 2025. PMID: 39313156 Free article. Clinical Trial.
410 results